Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
8.48
+0.42 (5.21%)
At close: Sep 26, 2025, 4:00 PM EDT
8.32
-0.16 (-1.89%)
After-hours: Sep 26, 2025, 4:28 PM EDT
Jade Biosciences Employees
Jade Biosciences had 30 employees as of December 31, 2024.
Employees
30
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,131,933
Market Cap
276.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JBIO News
- 25 days ago - Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy - GlobeNewsWire
- 4 weeks ago - Jade Biosciences to Participate in Upcoming Conferences - GlobeNewsWire
- 6 weeks ago - Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Jade Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Jade Biosciences Appoints Brad Dahms as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy - GlobeNewsWire
- 4 months ago - Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress - GlobeNewsWire
- 4 months ago - Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire